Omeros Newsroom

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

BenzingaDec 23 23:36

D. Boral Capital Initiates Omeros(OMER.US) With Buy Rating, Announces Target Price $36

Futu NewsDec 23 20:33 · Ratings

Omeros Initiated at Buy by D. Boral Capital

Dow JonesDec 23 20:19 · Ratings

D. Boral Capital Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $36

BenzingaDec 23 20:06 · Ratings

Needham Maintains Omeros(OMER.US) With Hold Rating

Futu NewsDec 21 02:43 · Ratings

Omeros (OMER) Gets a Hold From Needham

TipRanksDec 21 01:51 · Ratings

Needham Reiterates Hold on Omerosto Hold

BenzingaDec 20 17:40

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaDec 20 05:06

Sector Update: Health Care Stocks Lower Thursday Afternoon

MT NewswiresDec 20 02:49

Top Midday Gainers

MT NewswiresDec 20 02:38

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

BenzingaDec 20 01:28

Gold Falls Sharply, Lamb Weston Shares Plunge

BenzingaDec 20 01:24

Omeros Stock Gains 52% On Successful Trial Results

WSJDec 19 23:56

Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday

BenzingaDec 19 23:49

Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.

BenzingaDec 19 23:34

Omeros Up Over 66%, On Track for Highest Close Since September 2021 -- Data Talk

Dow JonesDec 19 23:27

Omeros' Pivotal Trial of Narsoplimab Meets Primary Endpoint

MT NewswiresDec 19 22:57

Express News | Omeros Corp: To Resubmit a Bla to FDA for Narsoplimab

BreakingsDec 19 22:20

Express News | Omeros' Narsoplimab Meets Its Pivotal Trial Primary Endpoint

BreakingsDec 19 22:19

Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges

Yahoo FinanceDec 11 01:22